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A b s t r A c t
Despite high levels of public awareness, the widespread use of automatic external de-
fibrillators and the ongoing education of doctors in advanced life support seminars, 
the percentage of victims who arrive at the hospital after out-of-hospital cardiac arrest 
(OHCA) is small. Of those who reach the hospital, the main cause of death in two 
thirds of the cases is persistent neurologic disability. The only therapy that has so far 
seemed to positively affect the neurological outcome of patients after cardiac arrest 
is mild therapeutic hypothermia (MTH). However, the application of MTH is also 
known to be associated with a number of potential adverse effects, and recent trials 
report on an increasing rate of stent thrombosis. If the results are confirmed, safe 
levels of temperature regulation would need to be defined. Recently, a study was pub-
lished that takes a critical approach to MTH. Hypothermia was compared to targeted 
temperature management near normothermia. After the end of the study period, 
there was no statistically significant difference regarding the survival to discharge 
and the neurological prognosis at 180 days. The authors stress that in both groups the 
temperature was actively controlled to avoid temperatures over 37 degrees Celsius. 
There followed few more publications with similar findings. The most important mes-
sage from these trial is that even if the aggressive regulation of temperature with the 
form of hypothermia may seem unjustified, this does not mean that fever should be 
left untreated. Normothermia is a goal that can be achieved rather easily and can also 
save the lives of many patients.
I N t r O D U c t I O N
Cardiac arrest is a major health problem in Western societies. Every year there 
are approximately 450,000 cardiac arrest victims in the USA1 and 325,000 in Europe.2 
Despite high levels of public awareness, the widespread use of automatic external de-
fibrillators and the ongoing education of physicians in advanced life support seminars, 
the percentage of victims who arrive at the hospital is small. The main cause of death 
in two thirds of cases that are admitted to hospital is persistent neurologic disability.3 
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In recent years it has been recognized that the treatment 
of victims of cardiac arrest does not end after the return of 
spontaneous circulation (ROSC), because post-cardiac arrest 
syndrome, a complex metabolic and pathophysiological process 
that results from the ischemia-reperfusion injury, demands a 
multidisciplinary approach through well-organized bundles of 
care.4 One of the cardinal manifestations of the syndrome is 
persistent brain damage, with mild therapeutic hypothermia 
(MTH) being the main form of treatment.
P O s t  c A r D I A c  A r r e s t  s y N D r O M e
Post-cardiac arrest syndrome is the result of pathophysi-
ological mechanisms that follow the cessation of circulation for 
a certain amount of time and subsequent reperfusion. The first 
observations of this clinical syndrome were made by Negovsky 
who named it “postresuscitation disease”.5 Today, post-cardiac 
arrest syndrome is defined as the unique and complex com-
bination of pathophysiological processes including: 1) brain 
dysfunction 2) myocardial dysfunction 3) systemic ischemia, 
and 4) unresolved precipitating pathology.6 The most signifi-
cant aspect of this syndrome and that with the most clinical 
implications is brain dysfunction.
The pathophysiology of brain dysfunction is not completely 
understood. In animal models, even relatively small periods 
of global ischemia are enough to cause degeneration in cer-
tain areas of the brain, such as the hippocampus, cerebellum, 
corpus striatum and the cerebral hemispheres.7 Bottiger et al 
showed that in mice, five minutes of reversible ischemia was 
enough time to observe neuronal DNA fragmentation and the 
expression of particular genes that lead to apoptosis of neural 
cells of the hippocampus.8
Today it is recognized that disorders of calcium homeo-
stasis, free radicals, brain edema, the no-reflow phenomenon 
and inflammation, all play an important role in the generation 
of neural injury. In short, after a period of ischemia lasting 
at least five minutes, there is ATP depletion resulting in 
neuronal membrane depolarization, opening of calcium and 
sodium channels and the influx of calcium ions into the cell. 
This process triggers the secretion of excitatory neurotrans-
mitters as well as kinase/phosphatase activation resulting in 
the expression of genes that induce apoptosis. The produc-
tion of free radicals as well as the inflammatory cascade that 
begins a few minutes after reperfusion and develops for hours 
or days, contribute to oxidative stress, lipolysis, proteolysis 
and eventually lead to cellular destruction. After inducing 
reversible ischemia in mice, Hosman et al observed that in all 
specimens there were areas of no-reflow positively correlated 
to the duration of ischemia. Low-flow can also be caused by 
the compression of the small vessels from brain edema, as well 
as by microthrombosis.
M I L D  t H e r A P e U t I c  H y P O t H e r M I A
The only therapy that has so far appeared to positively af-
fect the neurological outcome of patients after cardiac arrest is 
mild therapeutic hypothermia (MTH). Preliminary studies on 
animals have shown that hypothermia slows the biochemical 
cascade caused by the abrupt cessation and return of cerebral 
blood flow. The effects of hypothermia go beyond the tradi-
tional theory of decreased brain metabolism. Research has 
proven that hypothermia attenuates the disorders of calcium 
homeostasis and the resulting neuroexcitatory cell injury.9 
At the same time, hypothermia reduces free radical produc-
tion and lessens apoptosis. Hypothermia also attenuates the 
inflammatory reaction and might have beneficial effects on 
preserving the integrity of the blood brain barrier.
The first two landmark studies that applied MTH to hu-
mans were published in 2002.10,11 The first study was conducted 
in Australia and enrolled 77 patients with out-of-hospital car-
diac arrest.10 In order to be eligible for the study, patients had to 
have ventricular fibrillation (VF). Patients were assigned to the 
MTH group if they were admitted on odd-numbered days, and 
to the control group if they were admitted on even-numbered 
days. Of the 43 patients in the MTH group, 21 were discharged 
with a good neurological outcome, compared to only 9 of the 
35 control patients. The second study was a multicenter study 
conducted in Europe, which also exclusively enrolled patients 
with VF after out-of-hospital cardiac arrest.11 Randomly as-
signed patients received MTH of 32 - 34 degrees Celsius for 
24 hours, compared to the control group. Seventy-five of the 
136 (51%) patients receiving MTH had a good neurological 
outcome, in contrast to 54 of 137 (39%) of the control group. 
That study also found that people in the MTH group had an 
increased rate of survival at 6 months. The authors concluded 
that for every 6 patients that receive MTH, a life is saved.
The results were confirmed by a meta-analysis that in-
cluded 5 studies with 481 patients in total.12 Although different 
cooling methods were used in these studies, the results were 
consistent in demonstrating that MTH increases survival 
with a good neurological prognosis. The authors concluded 
that patients in the hypothermia group were more likely to 
reach a satisfactory neurological outcome, defined as cerebral 
performance category (CPC) 1 or 2 during hospital stay and 
were more likely to survive to hospital discharge compared to 
standard post-resuscitation care.
However, MTH is only one aspect of a broader support-
ive post-resuscitation strategy. All victims of cardiac arrest 
should be admitted to an intensive care unit (ICU) because 
they will need mechanical ventilation, hemodynamic support, 
continuous hemodynamic monitoring, as well as reliable 
core body temperature measurements. Before the induction 
of MTH, patients should be sufficiently sedated. Analgesia 
prevents patient discomfort and paralysis is used to avoid the 
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detrimental effects of shivering that increases metabolism, as 
well as heart rate and induces patient ventilator dyssynchrony. 
There are different methods for performing MTH, which can 
be categorized as invasive or non-invasive. One of the simplest 
approaches is ice packs, which offer a slow cooling rate of 0.9 
degrees Celsius per hour. There are also cooling blankets, as 
well as more sophisticated methods of non-invasive cooling, 
such as nasopharyngeal evaporative cooling. As for the invasive 
methods, the simplest technique is the infusion of cold fluids. 
There is also the insertion of specialized intravascular cooling 
catheters. Based on the studies that have been conducted so 
far, the outcome is similar irrespective of the cooling method.13
The application of MTH is also known to be associated 
with a number of potential adverse effects. One study which 
was conducted in 22 hospitals and enrolled 765 MTH patients 
found that pneumonia occurred in 48% of patients, electrolyte 
disturbances in 5-37%, seizures in 24% and arrhythmias (main-
ly bradyarrhythmias) in 7- 14%. Through multivariate analysis, 
hyperglycemia and seizures were found to be the major causes 
of mortality in these patients.14 MTH is also associated with 
thrombocytopenia and coagulation disorders. The first studies 
examining the feasibility of MTH with percutaneous coronary 
intervention (PCI) procedures focused on bleeding diathesis 
which was not statistically significant.15 A recent study com-
pared the pharmacodynamics of the newest platelet adenosine 
diphosphate (ADP)-P2y12 receptor inhibiting drugs in the 
setting of cardiac arrest, and found that victims of cardiac ar-
rest had significantly increased platelet reactivity, indicating a 
worse response to dual antiplatelet therapy.16 Another recent 
study reports on the rate of stent thrombosis in the setting of 
PCI after cardiac arrest. They retrospectively examined all 
patients who were admitted with acute myocardial infarction 
and received PCI in their institution. Repeated angiography 
was not performed routinely, but only in the case of clinical 
instability. Six out of 55 patients (10.9%) in the hypothermia 
group had a definite stent thrombosis, compared to three out 
of 153 (2.0%) p=0.01, in the control group.17 The authors 
concluded that despite the fact that cardiac arrest victims were 
not adequately premedicated with dual antiplatelet therapy, 
MTH could also be implicated.
MTH is considered a standard practice according to re-
suscitation guidelines for comatose victims of out-of-hospital 
cardiac arrest presenting with a shockable rhythm.18 Although 
MTH has been proven to have beneficial effects, there are still 
questions regarding its applications. First, even though the 
guidelines recommend the application of MTH to comatose 
victims of cardiac arrest with non-shockable rhythms, the 
benefits of this practice have not been confirmed by research. 
Second, although most centers follow the protocols set by the 
landmark trials, basic components of MTH are not yet well-
known, such as the onset and the rate of cooling, the duration 
of hypothermia, and the re-warming rate. Third, as was men-
tioned before, myocardial dysfunction is a basic component 
of post-cardiac arrest syndrome. The application of coronary 
angiography and PCI is becoming common practice as evi-
dence grows. The initial studies that combined PCI with MTH 
showed that hemorrhagic complications were not statistically 
significant. If the results of the recent trials regarding stent 
thrombosis are confirmed, there would be major problems 
with combining these two beneficial forms of treatment or 
at the very least, safe levels of temperature regulation would 
need to be defined.
t A r G e t e D  t e M P e r A t U r e 
M A N A G e M e N t  I N  s U r v I v O r s  
O F  O U t - O F - H O s P I t A L  c A r D I A c 
A r r e s t  ( O O H c A )
Recently, the Targeted Temperature Management (TTM) 
trial was published that takes a critical approach to MTH.19 
The authors based their hypothesis on the fact that there are 
no widely proven criteria for the absolute lowest temperature 
and on the fact that former studies had small samples. The 
study was conducted in 36 ICUs in Europe and Australia and 
its aim was to compare hypothermia to targeted temperature 
management near normothermia.19
The primary outcome of the study was survival to discharge 
and the secondary outcome was a favorable neurological 
prognosis at 6 months. Victims of out-of-hospital cardiac 
arrest (OOHCA) without obvious extracardiac cause over 
18 years old who remained comatose after sustained ROSC 
were included in the study, irrespective of the type of the first 
recorded rhythm. The exclusion criteria for the study were 
refractory shock, obvious or suspected extracardiac shock, 
pregnancy, and morbidity that precluded survival at 180 days. 
The patients were randomly assigned to discrete groups. In 
the hypothermia group, patients received hypothermia as 
soon as possible and remained at 33 degrees Celsius for 28 
hours, followed by a gradual re-warming period of 8 hours. In 
the normothermia group, patients received standard care, but 
their temperature was actively maintained within the normal 
range. After the 36-hour treatment, both groups received 
standard care with special care taken to avoid pyrexia. At 72 
hours, blinded external physicians performed neurological 
prognostication in order to withdraw life-sustaining therapy 
in cases of brain death.
After the end of the study period, the authors concluded 
that there was no statistically significant difference regarding 
the survival to discharge and the neurological prognosis at 
180 days. Survival to discharge was 50% in the hypothermia 
group (238 of 473 patients) versus 52% in the normothermia 
group (241 of 466 patients), p=0.51 and survival with a good 
neurological prognosis at 180 days was 46% (218 of 469 pa-
tients) versus 48% (222of 464 patients), p=0.78 respectively.19 
A subgroup analysis was conducted to test the effects of hy-
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pothermia among 6 different categories which were: gender, 
age over 65, presence of a shockable rhythm, time to ROSC 
over 25 minutes, and the presence of shock at admission. The 
results were consistent among the 6 specified subgroups and 
the authors stress that hypothermia did not prove to be more 
beneficial than normothermia in any of the subgroups. Other 
important findings of the study were that there was no statisti-
cal significance in the number of patients with shivering, nor 
in the number of hours with fever or temperature above 37.5 
degrees Celsius.
In another more recent randomized trial, 1359 adults with 
prehospital cardiac arrest with (n=583) and without VF (n= 
776), were assigned to standard care with or without prehospi-
tal cooling, following ROSC.20 Most patients resuscitated from 
VF and admitted to the hospital received hospital cooling re-
gardless of their randomization. Survival to hospital discharge 
was similar among the intervention and control groups among 
patients with VF (62.7% vs 64.3%; P=NS) and among patients 
without VF (19.2% vs 16.3%; P=NS). Neurological status 
was also similar for patients with VF (57.5% of cases had full 
recovery or mild impairment vs 61.9% of controls; P=NS) or 
those without VF (14.4% of cases vs 13.4% of controls; P=NS). 
Overall, the intervention group experienced rearrest in the 
field more than the control group (26% vs 21%; P=0.008). 
The authors concluded that although use of prehospital cool-
ing reduced core temperature by hospital arrival and reduced 
the time to reach a temperature of 34°C, it did not improve 
survival or neurological status among patients resuscitated 
from prehospital VF or those without VF.
Thus, these recent trials have cast doubts on the benefits 
and have raised questions about timing and temperature goals 
of induced hypothermia (Table 1). In another follow-up study 
of the latter trial, the association of prehospital hypothermia 
with neurological function at least 3 months after cardiac ar-
rest and survival 1 year after cardiac arrest was assessed in 508 
individuals who were discharged alive.21 Overall, the neuro-
logical status at 3 months, and 1-year survival (87% and 84%) 
of the two treatment groups were similar (P=NS). One-year 
survival was excellent for those with good neurological status at 
discharge, but very poor for those with impaired neurological 
status. The authors concluded that besides excellent survival, 
patients who had good neurological function at discharge con-
tinued to have good function at least 3 months after the event.
With regards to the timing of cooling, another randomized 
trial indicated that among 245 patients (123 having intra-arrest 
MTH and 122 in-hospital cooling) with OOHCA, the rate of 
patients admitted alive to hospital was not different between 
groups (33% vs 30%).22 Levels of biomarkers of neurological 
injury and inflammation were also similar and there was no 
difference in survival and cerebral performance found at 1 
month. The authors concluded that early (intra-arrest) MTH 
did not affect biological markers of inflammation or brain 
damage or clinical outcome.
Thus, the traditional concept of performing hypothermia 
on comatose patients with OOHCA may need to be re-exam-
ined. One possible explanation for the discordant results may 
relate to the fact that in previous studies, the temperature in 
the control group was not actively controlled and episodes of 
fever and hyperpyrexia could be the reason for the striking dif-
ference in neurological outcome and survival rates. However, 
tAbLe 1. Randomized studies comparing therapeutic hypothermia versus normothermia in cardiac arrest victims
study, year Patients 
(MtH/Nt)
vt/vF Initiation  
of cooling
MtH  
to/time  
to target  
cooling
Favorable  
neurologic  
outcome 
(rrr)
Death  
(rrr)
better  
(MtH  
vs Nt)
HAcA, 200211 275 (137/138) 265 105 min 33oC/480 min 55% vs 39% (40%)* 41% vs 55% (26%)* MTH
Australian, 
200210
77 (34 / 33) 77 <5 min 33oC/120 min 49% vs 26% (44%)* 51% vs 68% (25%) MTH
ttM, 201319 939 (473/466) 752 130 min 33oC/600 min 47% vs 48% 50% vs 48% Similar
seattle, 201420 1364 
(prehospital 
cooling)
583 <5-30 min 32oC-34oC/ 
252-330 min
58% vs 62% (VF)
14% vs 13% (no VF)
37% vs 36% (VF)
81% vs 84% (no VF)
Similar
tHAPcA-OH, 
201524
295 (155/140) 23 354 min 33oC/156 min 20% vs 12% 63% vs 72% Similar
HACA = hypothermia after cardiac arrest (study); MTH = mild therapeutic hypothermia; NT = normothermia; RRR = relative risk reduction; 
TTM = targeted temperature management (trial); VF = ventricular fibrillation; VT =ventricular tachycardia
*P <0.05
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the latter hypothesis is refuted by a retrospective study of chart 
review comparing cardiac arrest victims with sustained ROSC 
who did not receive MTH but never exceeded 37.5°C during 
the 36 hours postcardiac arrest with patients who received 
MTH.23 The study showed significantly more patients in the 
hypothermia group had a favorable neurological outcome 
(hypothermia: 256 of 467 or 55% vs normothermia: 69 of 165 
or 42%) and survived for >180 days (hypothermia: 315 of 467 
or 67% vs normothermia: 79 of 165 or 48%). The authors con-
cluded that MTH was associated with significantly improved 
neurological outcome and 180-day survival compared to spon-
taneous normothermia in cardiac-arrest patients.
Finally, the results of the TTM trial by Nielsen et al19 have 
just been recently corroborated in the pediatric population by 
the findings of the Therapeutic Hypothermia after Pediatric 
Cardiac Arrest Out-of-Hospital (THAPCA-OH) trial,24 which 
compared the efficacy of therapeutic hypothermia (target tem-
perature, 33°C) with that of therapeutic normothermia (target 
temperature, 36.8°C). Among 260 cardiac arrest victims, there 
was no significant difference in the primary outcome between 
the hypothermia group and the normothermia group (20% 
vs 12%; relative likelihood, 1.54; P=NS). The change in the 
neurologic status score from baseline to 12 months was not 
significantly different and 1-year survival was similar (38% in 
the hypothermia group vs 29% in the normothermia group; 
relative likelihood, 1.29; P=NS). The authors concluded that 
in comatose children who survived OOHCA, therapeutic 
hypothermia and normothermia conferred similar benefit in 
survival with a good functional outcome at 1 year.
A recent special report published in Circulation and ad-
dressing this critical issue concluded that for the time being 
“we should continue to cool most cardiac arrest patients to 
32 - 33°C, pending the results of further studies which should 
compare different temperature levels (32°C, 34°C, and 36°C) 
and determine optimal duration (24, 48, or 72 hours) of MTH, 
always with a slow (0.1 to 0.25°C/ hour) rewarming rate”, but 
admitted that “the results of the TTM trial clearly suggest that 
in some cardiac arrest patients strict fever control is sufficient 
to mitigate hypoxic injury”.25
A s s O c I A t e D  F A c t O r s  I N 
I M P L e M e N t I N G  t H e r A P e U t I c 
H y P O t H e r M I A
Despite the initial positive studies and guideline recom-
mendations, MTH utilization appears low in the real-world 
practice,26 probably due to several practical issues with its 
application. According to a Bostonian study, few hospitals 
appeared to perform MTH (47/419, 11.2%), but implementa-
tion appeared increasing over the study period (2006 – 2008).26 
Even in those cohorts in whom MTH is applied, several fac-
tors have been reported to predict outcome. According with a 
retrospective analysis of 170 consecutive patients treated with 
MTH, those 77 (45.2%) who survived to hospital discharge 
had a significantly lower maximum partial pressure of arterial 
oxygen (198 mmHg) measured in the first 24 hours following 
cardiac arrest compared to non-survivors (254 mmHg, p = 
0.022).27 Multivariate analysis including age, time to ROSC, 
presence of shock, bystander CPR, and initial rhythm revealed 
that hyperoxia with higher levels of the partial pressure of 
arterial oxygen was significantly associated with increased 
in-hospital mortality (odds ratio 1.439, p = 0.034) and poor 
neurologic status at hospital discharge (odds ratio 1.485, p = 
0.033).27 According with a retrospective analysis performed 
on 196 consecutive cardiac arrest survivors, presence of severe 
acidemia at initiation of MTH in shockable (but not in non-
shockable) patients was significantly associated with poor 
neurological outcomes.28
Patient admission temperature and use of cooling was as-
sessed in a prospective cohort of 177 comatose cardiac arrest 
patients treated with MTH (32–34oC, 24 hours) (median age 
61 years; median time to ROSC 25 min). Lower spontaneous 
admission body temperature and longer time of passive rewarm-
ing were associated with in-hospital mortality after cardiac 
arrest and MTH. The authors concluded that impaired ther-
moregulation may be an important physiologic determinant 
of post-resuscitation disease and cardiac arrest prognosis.29
According with a retrospective chart review of 194 consecu-
tive MTH-treated comatose post- cardiac arrest syndrome 
patients, time to awakening after resuscitation was highly 
variable and often longer than 3 days. Earlier awakening was 
associated with better neurologic status at hospital discharge. 
30 The role of target temperature was assessed in 36 cardiac 
arrest victims (26 shockable rhythm, 10 asystole), who were 
randomly assigned to 32°C (n=18) or 34°C (n=18), main-
tained during 24 hours followed by 12 to 24 hours of controlled 
rewarming. Eight of 18 patients in the 32°C group (44.4%) 
had better outcome compared with 2 of 18 in the 34°C group 
(11.1%) (log-rank P=0.12). All patients whose initial rhythm 
was asystole died before 6 months in both groups. Eight of 
13 patients with initial shockable rhythm assigned to 32°C 
(61.5%) were alive free from severe dependence at 6 months 
compared with 2 of 13 (15.4%) assigned to 34°C (log-rank 
P=0.029). The authors concluded that a lower cooling level 
may be associated with a better outcome in patients surviving 
OOHCA secondary to a shockable rhythm. 31
In a prospective, randomized controlled trial, 234 cardiac 
arrest victims with an initial cardiac rhythm of VF were as-
signed to either prehospital cooling by paramedics with a 
rapid infusion of 2 L of ice-cold lactated Ringer’s solution 
(n=118) or cooling after hospital admission (n=116).32 In 
the paramedic-cooled group, 47.5% patients had a favorable 
outcome at hospital discharge compared with 52.6% in the 
hospital-cooled group (risk ratio 0.90, P=0.43). The authors 
concluded that paramedic cooling with a rapid infusion of 
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large-volume, ice-cold intravenous fluid decreased core 
temperature at hospital arrival but was not shown to improve 
outcome at hospital discharge compared with cooling com-
menced in the hospital. 32
In another study of 80 OOHCA patients, hypothermia was 
induced after randomization by either invasive or noninvasive 
surface cooling at 33°C core body temperature for 24 hours 
followed by active rewarming.33 Neuron-specific enolase 
(NSE) levels used as a surrogate parameter for brain damage 
at 72 hours did not differ significantly between the 2 groups. 
Neurological and clinical outcome was similar in both groups. 
Target temperature of 33.0°C was maintained more stable in 
the invasive group (33 vs 32.7 °C, p <0.001). Bleeding com-
plications were more frequent with invasive cooling (43.6% vs 
17.9%; p = 0.03). The authors concluded that invasive cool-
ing has advantages with respect to temperature management 
over surface cooling, however, it did not result in improved 
outcome. Bleeding complications were more frequent with 
invasive cooling.33 In a similar study, 194 witnessed cardiac 
arrest patients were randomized to intra-arrest cooling with 
a RhinoChill device (n=93) vs standard care (n=101).34 A 
total of 18 device-related adverse events were reported. Time 
to target temperature of 34°C was shorter in the treatment 
group. There were no differences in rates of ROSC between 
the groups (38% vs 43%), in overall survival of those admit-
ted alive (44% vs 31%), or in neurologically intact survival to 
discharge (34% vs 21%). The authors concluded that prehos-
pital intra-arrest transnasal cooling is safe and feasible and is 
associated with a significant improvement in the time intervals 
required to cool patients but no difference in outcomes.34
c O N c L U s I O N
In conclusion, mild therapeutic hypothermia (MTH) is 
today a well-accepted treatment for victims of cardiac arrest, 
especially for those presenting with VF. As the amount of 
research grows, more concerns are arising about the absolute 
level of temperature control. The most important message 
from recent trials is that even if the aggressive regulation of 
temperature with the form of hypothermia may seem unjusti-
fied, this does not mean that fever should be left untreated, 
hence prevention of hyperthermia should be actively pursued. 
Normothermia is a goal that can be achieved rather easily and 
can also save the lives and brains of many patients. Finally, the 
apparent “failure” of MTH in recent trials to confer an im-
proved outcome compared to normothermia, might also be re-
lated to the recent advances in all other aspects of life support, 
which make it even harder to prove or disprove the beneficial 
effect of a single intervention in a clinical trial (http://blogs.
nejm.org/now/index.php/the-cold-truth-rethinking-tem-
perature-management-after-cardiac-arrest/2013/12/04/).
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